Novartis announced has entered an agreement that CSL has acquired its influenza vaccine business in a $275 million deal that will require regulatory approval before it closes by the end of the second half of 2015.
CSL has approximately 40 years of experience in the influenza vaccine business and operates in 27 counties around the world.
It has established businesses in plasma-driven therapies, pharmaceuticals, ant venoms and immunohemotology.
Novartis’ influenza vaccine business has a track record of delivering 1 billion doses of seasonal and pandemic influenza vaccines around the world over the past 30 years.
Novartis said it remains fully committed to its influenza business during the transition period.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity